Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 121

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 121
---
 securities;                |

| ● | assimilation of operations,                                                                                               
 intellectual property and drugs of an acquired company, including difficulties associated with integrating new personnel; |

| ● | the diversion of our management’s                                                                                          
 attention from our existing drug programs and initiatives in pursuing such a strategic partnership, merger or acquisition; |

| ● | retention of key employees,                                                                        
 the loss of key personnel and uncertainties in our ability to maintain key business relationships; |

| ● | risks and uncertainties                                                                                                             
 associated with the other party to such a transaction, including the prospects of that party and their existing products or product 
 candidates and marketing approvals; and                                                                                             |

| ● | Our inability to generate                                                                                                           
 revenue from acquired technology and/or products sufficient to meet our objectives in undertaking the acquisition or even to offset 
 the associated acquisition and maintenance costs.                                                                                   |

In addition, if we undertake
acquisitions, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses and acquire intangible
assets that could result in significant future amortization expense. Moreover, we may not be able to locate suitable acquisition opportunities,
and this inability could impair our ability to grow or obtain access to technology or products that may be important to the development
of our business.

<div align='center'>63</div>

Our Bylaws provide that the Court of Chancery of the State of Delaware and, to the extent enforceable, the federal district courts of the United States of America will be the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.

The Charter provides that,
unless we consent to the selection of an alternative forum, the Court of Chancery of the State of Delaware is the exclusive forum for
the following types of actions or proceedings under Delaware statutory or common law:

| ● | any derivative action or          
 proceeding brought on our behalf; |

| ● | any action asserting a    
 breach of fiduciary duty; |

| ● | any action asserting a                                                                                                              
 claim against us or any of our current or former directors, officers or other employees arising under the DGCL, the Charter, or the 
 Bylaws;                                                                                                                             |

| ● | any action seeking to interpret,                                        
 apply, enforce or determine the validity of this Charter or our Bylaws; |

| ● | any action as to which                                                               
 the DGCL confers jurisdiction on the Court of Ch